Literature DB >> 1732667

Chromosomal deletions in the myelodysplastic syndrome.

G J Mufti1.   

Abstract

Karyotypic abnormalities in primary myelodysplastic syndrome (P-MDS) are less frequent than in secondary myelodysplasia. A review of the literature involving over 3000 reported cases, shows the incidence of karyotypically abnormal clones at presentation in nearly 48% of cases. Approximately 50% of the abnormalities comprise of deletions of chromosomes 5, 7, 11, 12, 13 and 20. Localisation of a number of haemopoietic growth factors and their receptors to the deleted segments of the chromosomes, has invoked considerable interest in the molecular pathology of the interstitial deletions and their consequent role in the multistep pathogenesis of MDS. Present evidence suggests chromosome abnormalities are a later event in the multistep painogenesis, and it is suggested their occurrence may be restricted to a restricted myeloid progenitor cell, although the initial event(s) occur at the common lymphoid-myeloid progenitor. Much has been gleaned from the dominant modes of leukaemogenesis, such as the occurrence of missense mutations at specific positions of RAS and FMS mutations. It is suggested that a similar enquiry into the mechanisms of chromosomal deletions in P-MDS is required in order to delineate the role of these abnormalities in the clonal evolution of this group of diseases.

Entities:  

Mesh:

Year:  1992        PMID: 1732667     DOI: 10.1016/0145-2126(92)90097-q

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  7 in total

Review 1.  Biology and treatment of myelodysplastic syndromes--developments in the past decade.

Authors:  R Willemze; W E Fibbe; J H Falkenburg; J C Kluin-Nelemans; P M Kluin; J E Landegent
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

Review 2.  Chromosome and molecular abnormalities in myelodysplastic syndromes.

Authors:  Pierre Fenaux
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

Review 3.  Myelodysplastic syndromes: an update on molecular pathology.

Authors:  Mar Tormo; Isabel Marugán; Marisa Calabuig
Journal:  Clin Transl Oncol       Date:  2010-10       Impact factor: 3.405

4.  SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes.

Authors:  Manuel G Afable; Marcin Wlodarski; Hideki Makishima; Mohammed Shaik; Mikkael A Sekeres; Ramon V Tiu; Matt Kalaycio; Christine L O'Keefe; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

Review 5.  Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS).

Authors:  Peter Valent; Friedrich Wimazal; Ilse Schwarzinger; Wolfgang R Sperr; Klaus Geissler
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

6.  FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q).

Authors:  Hideki Makishima; Manjot Rataul; Lukasz P Gondek; Jungwon Huh; James R Cook; Karl S Theil; Mikkael A Sekeres; Elizabeth Kuczkowski; Christine O'Keefe; Jaroslaw P Maciejewski
Journal:  Leuk Res       Date:  2009-09-15       Impact factor: 3.156

Review 7.  Recent-onset myelodysplastic syndrome mimicking acute leukemia during infection.

Authors:  H D Friedman; S A Landaw
Journal:  Ann Hematol       Date:  1996-02       Impact factor: 3.673

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.